BidaskClub upgraded shares of Cellectis (NASDAQ:CLLS) from a strong sell rating to a sell rating in a report published on Tuesday, September 18th.
A number of other analysts have also recently commented on the company. ValuEngine cut Cellectis from a buy rating to a hold rating in a research report on Tuesday, September 11th. Barclays started coverage on Cellectis in a research report on Monday, July 16th. They issued an overweight rating and a $50.00 price objective for the company. Oppenheimer boosted their price objective on Cellectis from $40.00 to $44.00 and gave the company an outperform rating in a research report on Tuesday, June 12th. Finally, Zacks Investment Research cut Cellectis from a buy rating to a hold rating in a research report on Tuesday, July 10th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $49.20.
CLLS stock traded up $1.09 during trading on Tuesday, hitting $27.03. 432,313 shares of the company traded hands, compared to its average volume of 209,448. The stock has a market cap of $1.17 billion, a P/E ratio of -9.72 and a beta of 1.84. Cellectis has a 1 year low of $22.62 and a 1 year high of $38.85.
Cellectis (NASDAQ:CLLS) last announced its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.45. The company had revenue of $8.34 million during the quarter, compared to analysts’ expectations of $9.43 million. Cellectis had a negative return on equity of 25.46% and a negative net margin of 281.38%. Research analysts anticipate that Cellectis will post -2.15 EPS for the current year.
Institutional investors have recently bought and sold shares of the company. JBF Capital Inc. purchased a new stake in shares of Cellectis in the second quarter valued at approximately $1,697,000. ARK Investment Management LLC boosted its stake in shares of Cellectis by 178.8% in the second quarter. ARK Investment Management LLC now owns 244,263 shares of the biotechnology company’s stock worth $6,910,000 after acquiring an additional 156,666 shares during the last quarter. UBS Group AG boosted its stake in shares of Cellectis by 143.1% in the first quarter. UBS Group AG now owns 15,383 shares of the biotechnology company’s stock worth $485,000 after acquiring an additional 9,054 shares during the last quarter. Vident Investment Advisory LLC boosted its stake in shares of Cellectis by 30.3% in the second quarter. Vident Investment Advisory LLC now owns 80,527 shares of the biotechnology company’s stock worth $2,278,000 after acquiring an additional 18,730 shares during the last quarter. Finally, Bellevue Group AG boosted its stake in shares of Cellectis by 114.0% in the first quarter. Bellevue Group AG now owns 52,100 shares of the biotechnology company’s stock worth $1,642,000 after acquiring an additional 27,750 shares during the last quarter. Institutional investors and hedge funds own 27.10% of the company’s stock.
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Further Reading: How to Invest in the Dividend Aristocrat Index
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.